Effect of Altitude on Postdural Puncture Headache After Caesarean Delivery

Sponsor
B.P. Koirala Institute of Health Sciences (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05804448
Collaborator
Karnali Academy of Health Sciences (Other)
292
2
24.3
146
6

Study Details

Study Description

Brief Summary

The aim of this study is to examine the effects of altitude (high altitude versus low altitude) on incidence and severity of postural puncture headache (PDPH) following spinal anaesthesia for caesarean delivery. The investigators hypothesized that the risk of PDPH would be higher in highlander parturients than in lowlander parturients.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This will be a prospective cohort study conducted in two different altitudes in Nepal. The high-altitude site is in Jumla, approximately 2514 m above the sea level, and a low altitude city is Dharan, located at 350 m from sea level.

    The investigators will screen the eligible participant admitted to the in-patient obstetric unit. The investigator will also record patient baseline characteristics, preoperative anxiety, antenatal depression, presence of chronic pain conditions or preexisting headache. Spinal anaesthesia will be administered in the sitting position at the L3-L4 or L4-L5 interspace using a 25-G pencil point spinal needle (Pencan® 25-gauge).

    The diagnosis of post-dural puncture headache will be based on the international headache society ICDH-3 criteria

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    292 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Effect of Altitude on Postdural Puncture Headache After Caesarean Delivery: a Prospective, Multicentre Cohort Study
    Anticipated Study Start Date :
    Apr 10, 2023
    Anticipated Primary Completion Date :
    Jan 20, 2025
    Anticipated Study Completion Date :
    Apr 20, 2025

    Arms and Interventions

    Arm Intervention/Treatment
    High-altitude group

    Parturient who are native to their resident altitude, i.e. residing at the altitude above 2500 m from sea level will receive spinal anesthesia for caesarean section.

    Low-altitude group

    Parturient who are native to their resident altitude, i.e. residing at the altitude below 500 m from sea level will receive spinal anesthesia for caesarean section.

    Outcome Measures

    Primary Outcome Measures

    1. Number of patients with postdural puncture headache [up to 7 days after spinal anesthesia]

      The diagnosis of post-dural puncture headache will be based on the international headache society ICDH-3 criteria: a headache that occurs within 5 days of a dural puncture, is located in the occipital and/or frontal areas, worsens within 15 min of sitting or standing and alleviates within 15 min after lying down, associated with at least one of the following features: neck stiffness, nausea, vomiting, photophobia, and tinnitus, and resolves either spontaneously within 1 week or within 48 h after effective treatment.

    Secondary Outcome Measures

    1. Number of patients with severity of postdural puncture headache [up to 7 days after spinal anesthesia]

      using a numeric rating scale (NRS), with 0= NO pain 10=worst imaginable pain, and classified as none (NRS=0), mild (1-3), moderate (4-6), and severe (7-10)

    2. Pain assessed by PROMIS pain interference scale [7 days after occurrence of postdural puncture headache]

      6-item PROMIS Pain Interference short form scale will be used to assess the self-reported consequences of PDPH on social, cognitive, physical, and recreational activities. Respondents will be asked to rate the interference of pain in each activity listed using a 1 to 5 scale, where 1 = Not at all. 2 = A little bit, 3 = Somewhat, 4 = Quite a bit, and 5 = Very much

    3. Number of patients with non-postdural puncture headache [up to 7 days after spinal anesthesia]

      Headache that is not related to posture

    4. Number of patients who received treatment for postdural puncture headache [up to 1 month after occurrence of PDPH]

      paracetamol, NSAID's, caffeine, opioids, glossopharyngeal nerve block, sphenopalatine ganglion block and epidural blood patch

    5. Number of patient with chronic headache [At 1 and 3 months after occurrence of headache following spinal anesthesia]

      Headache that is persistent after postdural puncture headache or after non-postdural puncture headache

    6. Number of patients with chronic backache [At 1 and 3 months after spinal anesthesia]

      Presence of backache after spinal anesthesia

    7. Number of patients with chronic post surgical pain [3 month after caesarean section]

      Pain that develops or increases in intensity after cesarean section and persists at least 3 months after the surgery. The pain has to be localised to the surgical field or area of injury. Other causes of pain such as pre-existing pain conditions or infections, or malignancy etc. have to be excluded.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Inclusion Criteria:
    • Parturient, aged more than or equal to 18 years

    • American society of Anesthesiologist 2 and 3

    • Scheduled for elective and non-elective (category 2 & 3) caesarean delivery with spinal anesthesia

    • Native to their resident altitude i.e., those born, raised, and have continuously lived at the same altitude, at least for the past 1 year.

    Exclusion Criteria:
    • Hypertensive disorder

    • Cerebrovascular disease

    • Mental disorder (schizophrenia and other psychotic disorders)

    • Known fetal anomalies

    • Contraindication to spinal anaesthesia.

    • Those requiring general anaesthesia for delivery due to failed spinal anesthesia

    • Major post-delivery complications (severe haemorrhage, sepsis, or ICU admission)

    • Those who migrate from their resident altitude (either low to high or vice versa) within 7 days post-delivery will also be excluded.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Karnali Academy of Health Sciences Jumla Karnali Nepal 2069
    2 BP Koirala Institute of Health Sciences (BPKIHS) Dharān Bāzār Koshi Nepal 56700

    Sponsors and Collaborators

    • B.P. Koirala Institute of Health Sciences
    • Karnali Academy of Health Sciences

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Dr Asish Subedi, Principal Investigator, B.P. Koirala Institute of Health Sciences
    ClinicalTrials.gov Identifier:
    NCT05804448
    Other Study ID Numbers:
    • 533/2022 P
    First Posted:
    Apr 7, 2023
    Last Update Posted:
    Apr 11, 2023
    Last Verified:
    Apr 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Dr Asish Subedi, Principal Investigator, B.P. Koirala Institute of Health Sciences
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 11, 2023